Hsieh Lab

Are you looking for a postdoctoral position where you will be challenged to dig deep into the post-transcriptional mechanisms of cancer? If so, check out @HsiehLab @fredhutch, we have an opening (careers-fhcrc.icims.com/jobs/30066/pos…)! Website: research.fredhutch.org/hsieh/en.html

@FaltasLab @Uroweb @AStenzl @MaartenAlbersen @WCMDeptofMed @WCMEnglanderIPM @IBCG_BladderCA @urotoday @ASCOPost @nyphospital @EUplatinum @HemOncToday @ElementoLab @notSoJunkDNA Congrats Bishoy!

Thank you @Uroweb #EAU26 @AStenzl @MaartenAlbersen for this recognition of our research. Much more work to be done to advance the field. A deep understanding of biology of #bladdercancer is essential for the next-wave of therapeutic development #FaltasLab @WCMDeptofMed @WeillCornell @Cornell

Go Dr. Rosa Nadal @fredhutch!

Big congrats @li_haolong!

Congrats @li_haolong

Huge congratulations to the recipients of the 2026 Weintraub Award! These twelve exceptional graduate students exemplify the bold, creative, and pioneering spirit embodied by Dr. Hal Weintraub. fredhutch.org/en/news/releas…

Cutting edge research team. Check them out!

Please spread the word. We have open positions for outstanding postdoctoral researchers interested in studying the mechanisms of cancer evolution and new ways to intercept it! #Hiring #Postdoc #ScienceTwitter #CancerResearch #CancerBiology Details below:

We applied plasma epigenomic profiling (pioneered across many prior #FreedmanLab studies) to #translocationRCC, a genomically quiet and often challenging-to-diagnose kidney cancer where mutation‑based cfDNA assays have variable performance. [2]

Our latest paper is now out in @jclinicalinvest! 🎉Huge congrats to superstars🌟 @simongarinet & @karlsemaan on this study with @sylvanbacalab #FreedmanLab @drchoueiri. [1]

By detecting a distinctive TFE3‑driven epigenomic signature in plasma, we could distinguish tRCC from ccRCC and non‑cancer samples even at low tumor fraction. Link 👇 jci.org/articles/view/… [3]

Excited for two great speakers at Friday Afternoon Seminars! For everyone @FredHutch, join us at 4:00 in Pelton to hear Mehedi Hassan from the @BuckLB14 Lab and Rashmi Mishra from Human Biology’s @HsiehLab share their latest discoveries!

@FaltasLab @AACR @WCMGUcancer @WCMDeptofMed @WCM_MeyerCancer @WCMEnglanderIPM @WeillCornell Congrats Bishoy!

Honored to receive the American Association for Cancer Research @AACR 2025 Grant for Innovative #BladderCancer Research @WCMGUcancer @WCMDeptofMed @WCM_MeyerCancer @WCMEnglanderIPM @WeillCornell

Merry Christmas to all from the Faltas Lab🎄This year, Santa 🎅 brought us spatial single-cell gifts 🎁, which we plan to share with all with a public release of our CLONEVO #bladdercancer clinical trial #IMC dataset @WCMEnglanderIPM @WCMGUcancer @WeillCornell

Merry Christmas & Happy Holidays! Please consider opening this important phase 3 trial asking the major ICI rechallenge question in advanced urothelial Ca! @MonikaJoshimd @eaonc @arkhaki @JasonBrownMDPhD @OncBrothers @OncoAlert @Parminder1699 opening soon at @fredhutch @HsiehLab

@FaltasLab @WeillCornell @Cornell @HeartBobH @DrScottTagawa @DrDavidNanus @DrChoueiri @ChongPan_HMS @montypal @PGrivasMDPhD @MarkARubin1 @ElementoLab Congrats man!

#Tenure! I’m overwhelmed with gratitude to share that I’ve been awarded tenure at @WeillCornell @Cornell I’m deeply grateful to my family, mentors, collaborators, and the many friends and colleagues in the field who have supported me in so many ways over the years. Too many names to list here! Thank you to every single one of you. To the #FaltasLab members and alumni, your creativity, persistence, and teamwork made this possible. You’ve made me better in every way, and it’s a privilege to witness your growth and successes. This truly belongs to all of you. As I reflect on this journey, I’m reminded of the challenges we’ve overcome, and of the profound privilege of being a physician-scientist: caring for patients with #bladdercancer, doing cutting-edge science, and mentoring the next generation of bright minds. The next chapter is about asking bigger questions and building new bridges, between science and medicine, and between people! @WCMEnglanderIPM @WCM_MeyerCancer With passion, persistence, and humility, onward!

Am so excited about the initiative, looking forward to thoughts; audience is broad! 1st episode link below, more coming soon! youtu.be/1AbYwCQbcNY?si… @fredhutch @montypal @neerajaiims @UroDocAsh @HsiehLab @spsutkaMD @OncoAlert @g_mountzios @mtsiatas @DRBakaloudiMD @OncBrothers

📢 Excited to share the latest from our lab: we discovered a new synthetic-lethal vulnerability in cancer cells with APOBEC3A activity and its underlying mechanism 🔧🧩 -APOBEC3A induces DNA double-strand breaks🧬✂️🧬 - APOBEC3A shifts double-strand DNA break repair towards POLθ-mediated end joining 🛠️🪢 by competing with RPA for ssDNA overhangs 🧵.This exposes microhomology sequences engaging POLθ-mediated repair. -We see the correlation between the mutational footprints of these two processes: APOBEC3A-induced mutational signatures and specific indels from error-prone POLθ repair in thousands of human cancers -Inhibiting POLθ selectively eliminates #bladdercancer cells with APOBEC3A activity in vitro 🧫 and in vivo 🐁 - APOBEC3A-driven mutagenesis fuels cancer evolution. We view this work as a foundation for a potential therapeutic approach to selectively deplete APOBEC3A-active cancer cells, removing adaptation-prone clones from the evolutionary pool 🎇. POLθ inhibitors are already in early-phase clinical trials (e.g., ART6043, RP-3467, GSK4524101, novobiocin) ➡️ Link🔗 biorxiv.org/content/10.110… #bladdercancer #CancerResearch #SyntheticLethality #APOBEC3A

@rosslevinemd Congrats!

Hurray!

We’ve been busy 🐝s! Happy to share 5️⃣new preprints from the lab: one-liners below 👇#translocationRCC #CancerResearch @danafarber_GU [0/6]